AOD-9604
HGH C-Terminal Fragment — Fat Metabolism Without Growth Effects
Weight Management & Metabolism
Version 2025-04 · Last Reviewed April 1, 2025
About this review (v2025-04, last reviewed April 1, 2025): This review was compiled from published preclinical and clinical research, FDA regulatory documents, and compounding pharmacy guidance. No peptide vendor or manufacturer reviewed or approved this content. Read our full methodology
Educational content only. This page reflects published research and does not constitute medical advice. Peptides are not FDA-approved drugs (with limited exceptions noted). Consult a licensed healthcare provider before use. Dosing is intentionally omitted — it is determined by your provider based on individual labs and goals.
What it is
AOD-9604 is a synthetic fragment corresponding to the C-terminal amino acids 177–191 of human growth hormone (HGH). It was specifically designed to retain the fat-metabolism properties of HGH without the growth-promoting, insulin-resistance, or IGF-1-elevating effects of the full HGH molecule. Animal studies and early human trials suggested meaningful effects on fat cell lipolysis (breakdown) and lipogenesis (fat storage) inhibition. Phase IIb human obesity trials showed acceptable safety — but Phase III did not show sufficient efficacy for FDA drug approval.
Regulatory status
Not FDA-approved for any indication. AOD-9604 (Advanced Obesity Drug) was developed by Metabolic Pharmaceuticals (Australia). It received GRAS (Generally Recognized as Safe) designation for oral use from the FDA in 2014, but this applies to use as a food ingredient — not as a drug or injectable. It is not DEA scheduled. Compounding pharmacies can compound for injectable use under physician prescription.
Mechanism of Action
AOD-9604 is believed to activate a specific fat cell receptor pathway that promotes lipolysis (fat cell breakdown) and inhibits lipogenesis (fat storage creation). Unlike full HGH, it does not appear to bind the primary growth hormone receptor significantly, meaning it does not raise IGF-1, does not promote cell growth, and does not impair insulin sensitivity in clinical studies. The precise receptor remains under investigation but likely involves beta-3 adrenergic receptor signaling in adipose tissue.
What Research Has Explored
These are areas of published research — not personal recommendations.
Obesity / weight loss
Phase IIa and IIb trials demonstrated statistically significant weight loss in obese adults compared to placebo. Phase III trials did not replicate this effect at the required magnitude for drug approval.
Context: The gap between early and late-stage trial results is a common pattern — Phase IIb success does not guarantee Phase III success. The drug development program was discontinued.
Metabolic effects on fat tissue
AOD-9604 appears to promote fat cell lipolysis and inhibit lipogenesis in both animal models and in vitro studies, without affecting blood glucose, IGF-1, or growth hormone levels.
Context: The metabolic mechanism appears real even though the clinical weight loss effect in Phase III was insufficient for drug approval. The question is whether subclinical fat metabolism effects have practical benefit.
Osteoarthritis (cartilage)
AOD-9604 has been studied for cartilage repair in osteoarthritis animal models and has entered Phase II trials for this indication under the name Epitope-based peptide AOD.
Context: Cartilage applications are at early human trial stage. Do not interpret as proven treatment.
Stability & Delivery Form — Why This Matters
Most peptides are fragile molecules destroyed by stomach acid and digestive enzymes. Delivery form determines whether the peptide survives to reach your bloodstream.
Capsule / Pill Warning
AOD-9604 in capsule or pill form has no meaningful systemic bioavailability. Stomach acid and digestive enzymes destroy the peptide bonds before absorption. If a product is sold as a capsule claiming the systemic effects of the injectable form, it cannot deliver those effects. This is a red flag about the vendor's credibility.
Subcutaneous injection (lyophilized powder, reconstituted)
The primary studied route. Must be reconstituted from lyophilized powder with bacteriostatic water and refrigerated.
Oral (as food ingredient — GRAS status only)
AOD-9604 received FDA GRAS designation for oral use as a food ingredient — not as a drug. Oral bioavailability for drug-like systemic effects is negligible (peptide bonds are broken down in the GI tract). Oral capsules claiming the metabolic effects of injectable AOD-9604 cannot deliver those effects.
Reconstitution & Storage
Reconstitute lyophilized powder with bacteriostatic water. Refrigerate at 2–8°C. Stability approximately 20–30 days refrigerated. Do not freeze reconstituted peptide. Protect from light.
Dosing is intentionally not listed here. It is determined by your provider based on individual labs, goals, and clinical context.
Frequently Asked Questions About AOD-9604
- What is AOD-9604?
- AOD-9604 is a synthetic fragment corresponding to the C-terminal amino acids 177–191 of human growth hormone (HGH). It was specifically designed to retain the fat-metabolism properties of HGH without the growth-promoting, insulin-resistance, or IGF-1-elevating effects of the full HGH molecule. Animal studies and early human trials suggested meaningful effects on fat cell lipolysis (breakdown) and lipogenesis (fat storage) inhibition. Phase IIb human obesity trials showed acceptable safety — but Phase III did not show sufficient efficacy for FDA drug approval.
- What is AOD-9604 used for in research?
- AOD-9604 has a well-characterized safety profile from formal Phase II/III human trials and a plausible fat-selective mechanism, but failed to demonstrate sufficient weight loss efficacy for drug approval — positioning it as safe but with uncertain individual benefit. Research areas include: Obesity / weight loss, Metabolic effects on fat tissue, Osteoarthritis (cartilage).
- Is AOD-9604 FDA approved?
- Not FDA-approved for any indication. AOD-9604 (Advanced Obesity Drug) was developed by Metabolic Pharmaceuticals (Australia). It received GRAS (Generally Recognized as Safe) designation for oral use from the FDA in 2014, but this applies to use as a food ingredient — not as a drug or injectable. It is not DEA scheduled. Compounding pharmacies can compound for injectable use under physician prescription.
- How is AOD-9604 administered?
- Subcutaneous injection only (for drug-like metabolic effects)
- What are the safety risks of sourcing AOD-9604?
- Key risks when sourcing AOD-9604 from grey-market or research suppliers include: AOD-9604's failed Phase III means grey market vendors may make exaggerated weight loss claims unsupported by completed clinical evidence.; Standard contamination, mislabeling, and adulteration risks of all grey market injectables apply.; GRAS status for oral use is frequently misrepresented by grey market sellers as evidence of safety for injectable use — these are entirely separate regulatory pathways..
- Who should avoid or be cautious about AOD-9604?
- AOD-9604 should be used with caution or avoided by: Active cancer — promotes fat cell metabolism; theoretical concern with malignancy (though mechanistic risk differs from growth-promoting peptides).; Pregnancy and breastfeeding — no safety data.; Children and adolescents — no safety or efficacy data..
Stay informed — get updates when we add new medications
We add new medications and supplements regularly. No spam, ever.
No spam. Unsubscribe anytime.